BACKGROUND: Atherosclerosis is widely accepted as an inflammatory disease involving both innate and adaptive immunity. B cells and/or antibodies have previously been shown to play a protective role against atherosclerosis. Aside from their ability to bind to antigens, antibodies can influence inflammatory responses by interacting with various Fcγ receptors on the surface of antigen presenting cells. Although studies in mice have determined that stimulatory Fcγ receptors contribute to atherosclerosis, the role of the inhibitory Fcγ receptor IIb (FcγRIIb) has only recently been investigated. METHODS AND RESULTS: To determine the importance of FcγRIIb in modulating the adaptive immune response to hyperlipidemia, we generated FcγRIIb-deficient mice on the apoE-deficient background (apoE/FcγRIIb(-/-)). We report that male apoE/FcγRIIb(-/-) mice develop exacerbated atherosclerosis that is independent of lipid levels, and is characterized by increased antibody titers to modified LDL and pro-inflammatory cytokines in the aorta. CONCLUSIONS: These findings suggest that antibodies against atherosclerosis-associated antigens partially protect against atherosclerosis in male apoE(-/-) mice by conveying inhibitory signals through the FcγRIIb that downregulate pro-inflammatory signaling via other immune receptors. These data are the first to describe a significant in vivo effect for FcγRIIb in modulating the cytokine response in the aorta in male apoE(-/-) mice. Copyright Â
BACKGROUND:Atherosclerosis is widely accepted as an inflammatory disease involving both innate and adaptive immunity. B cells and/or antibodies have previously been shown to play a protective role against atherosclerosis. Aside from their ability to bind to antigens, antibodies can influence inflammatory responses by interacting with various Fcγ receptors on the surface of antigen presenting cells. Although studies in mice have determined that stimulatory Fcγ receptors contribute to atherosclerosis, the role of the inhibitory Fcγ receptor IIb (FcγRIIb) has only recently been investigated. METHODS AND RESULTS: To determine the importance of FcγRIIb in modulating the adaptive immune response to hyperlipidemia, we generated FcγRIIb-deficient mice on the apoE-deficient background (apoE/FcγRIIb(-/-)). We report that male apoE/FcγRIIb(-/-) mice develop exacerbated atherosclerosis that is independent of lipid levels, and is characterized by increased antibody titers to modified LDL and pro-inflammatory cytokines in the aorta. CONCLUSIONS: These findings suggest that antibodies against atherosclerosis-associated antigens partially protect against atherosclerosis in male apoE(-/-) mice by conveying inhibitory signals through the FcγRIIb that downregulate pro-inflammatory signaling via other immune receptors. These data are the first to describe a significant in vivo effect for FcγRIIb in modulating the cytokine response in the aorta in male apoE(-/-) mice. Copyright Â
Authors: Onno J de Boer; Jelger J van der Meer; Peter Teeling; Chris M van der Loos; Mirza M Idu; Febe van Maldegem; Jan Aten; Allard C van der Wal Journal: J Pathol Date: 2010-03 Impact factor: 7.996
Authors: T van Es; G H M van Puijvelde; O H Ramos; F M E Segers; L A Joosten; W B van den Berg; I M Michon; P de Vos; Th J C van Berkel; J Kuiper Journal: Biochem Biophys Res Commun Date: 2009-08-04 Impact factor: 3.575
Authors: Dorette Raaz; Martin Herrmann; Arif B Ekici; Lutz Klinghammer; Berthold Lausen; Reinhard E Voll; Jeanette H W Leusen; Jan G J van de Winkel; Werner G Daniel; André Reis; Christoph D Garlichs Journal: Atherosclerosis Date: 2009-01-21 Impact factor: 5.162
Authors: Elena Galkina; Alexandra Kadl; John Sanders; Danielle Varughese; Ian J Sarembock; Klaus Ley Journal: J Exp Med Date: 2006-05-08 Impact factor: 14.307
Authors: Jillian P Rhoads; John R Lukens; Ashley J Wilhelm; Jared L Moore; Yanice Mendez-Fernandez; Thirumala-Devi Kanneganti; Amy S Major Journal: J Immunol Date: 2017-01-27 Impact factor: 5.422
Authors: Shaun W Jackson; Nicole E Scharping; Holly M Jacobs; Shari Wang; Alan Chait; David J Rawlings Journal: J Immunol Date: 2016-11-11 Impact factor: 5.422